This compound, known as norbinaltorphimine (nor-BNI), is primarily utilized in research settings as a potent and selective antagonist for the kappa-opioid receptor. It is particularly valuable in pharmacological studies of opioid signaling pathways, receptor interactions, and related biological mechanisms. Researchers use it to investigate the modulation of cellular responses, understand kappa-opioid receptor function, and explore potential therapeutic applications in areas such as pain management, addiction, and mood disorders. Its unique binaltorphimine-derived structure enables highly selective binding to the kappa receptor, offering insights into the design of targeted drugs with reduced off-target effects. Additionally, it serves as a key tool compound in biochemical and pharmacological assays to elucidate the role of kappa-opioid receptors in various disease models.